Lipella Pharmaceuticals Presents Promising Phase 2a Trial Data

An announcement from Lipella Pharmaceuticals, Inc. ( (LIPO) ) is now available.

On May 15, 2025, Lipella Pharmaceuticals announced that topline data from its ongoing Phase 2a trial of LP-310 for Oral Lichen Planus will be presented at an international meeting in Las Vegas. The data, which includes safety and efficacy findings from two dose cohorts, showed statistically significant improvements in multiple endpoints, supporting LP-310’s potential as a localized, non-steroidal treatment. The trial demonstrated that LP-310 was well tolerated with no serious adverse events, highlighting its promise in addressing unmet medical needs.

The most recent analyst rating on (LIPO) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Lipella Pharmaceuticals, Inc. stock, see the LIPO Stock Forecast page.

More about Lipella Pharmaceuticals, Inc.

Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. The company targets diseases with significant unmet needs, where no approved drug therapies currently exist.

Average Trading Volume: 95,713

Technical Sentiment Signal: Sell

Current Market Cap: $6.1M

For a thorough assessment of LIPO stock, go to TipRanks’ Stock Analysis page.